5-Fluorouracil targets thymidylate synthase in the selective suppression of TH17 cell differentiation
- Juan Wang,
- Liang Peng,
- Ruihua Zhang,
- Zihan Zheng,
- Chun Chen,
- Ka Lung Cheung
- Icahn School of Medicine at Mount Sinai,
- Southern Medical University,
- University of North Carolina at Chapel Hill,
- Virginia Polytechnic Institute and State University,
- Amgen Incorporated,
- Tempero Pharmaceuticals
Open access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
While it is well established that treatment of cancer patients with 5-Fluorouracil (5-FU) can result in immune suppression, the exact function of 5-FU in the modulation of immune cells has not been fully established. We found that low dose 5-FU selectively suppresses TH17 and TH1 cell differentiation without apparent effect on Treg, TH2, and significantly suppresses thymidylate synthase (TS) expression in TH17 and TH1 cells but has a lesser effect in tumor cells and macrophages. Interestingly, the basal expression of TS varies significantly between T helper phenotypes and knockdown of TS significantly impairs TH17 and TH1 cell differentiation without affecting the differentiation of either Treg or TH2 cells. Finally, low dose 5-FU is effective in ameliorating colitis development by suppressing TH17 and TH1 cell development in a T cell transfer colitis model. Taken together, the results highlight the importance of the anti-inflammatory functions of low dose 5-FU by selectively suppressing TH17 and TH1 immune responses.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 19312-19326 (15 pages)Journal (Volume, Issue Number)
Oncotarget (Volume 7, Issue 15)Publication milestones
- Published - 04/12/2016
Publication status
ISSN
1949-2553Publication IDs
- Scopus: 84964727150
- PubMed: 27027355
